Gastrointestinal Cancer | Specialty

Study Shows DAAs Are Not Associated With Increased HCC Recurrence Risk

September 18th 2017

Direct acting antivirals are a novel and completely oral hepatitis C therapy that is associated with a high response rate in hepatocellular carcinoma (HCC).

BLU-554 Associated With Improved Response in HCC

September 17th 2017

BLU-554 induced an overall response rate of 16% in patients with FGF19-positive hepatocellular carcinoma.

Dr. Welling on CheckMate-040 Trial of Nivolumab in HCC

September 17th 2017

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the purpose of the CheckMate-040 trial, which explored nivolumab (Opdivo) in patients with hepatocellular carcinoma. (HCC).

Dr. Montal on Molecular Predictors of Recurrence With Adjuvant Sorafenib in HCC

September 17th 2017

Robert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses biomarker findings of the phase III STORM trial, which explored adjuvant treatment with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

Lenvatinib Continues to Show Noninferiority to Sorafenib in Liver Cancer

September 17th 2017

First-line therapy with lenvatinib continued to be noninferior in overall survival and achieve significant improvements in progression-free survival, time to progression, and objective response rate compared with sorafenib for patients with unresectable hepatocellular carcinoma.

STORM Study Fails to Find Predictive Biomarkers for Sorafenib in HCC

September 16th 2017

Hepatocyte pERK-positive immunostaining and microvascular invasion were independent prognostic factors of recurrence-free survival for patients with hepatocellular carcinoma treated with adjuvant sorafenib; however, a predictive biomarker for recurrence was not uncovered.

Precision Screening May Improve Surveillance in HCC

September 16th 2017

Precision screening for hepatocellular carcinoma (HCC) could improve on current screening techniques through its risk-stratifying approach.

Dr. Finn on Significance of Phase III Findings of Lenvatinib in HCC

September 16th 2017

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the significance of the phase III trial of frontline lenvatinib (Lenvima) versus sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

Dr. Welling on Incorporating Immunotherapy Into HCC Paradigm

September 16th 2017

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses how immunotherapy agents will eventually fit into the paradigm of hepatocellular carcinoma. (HCC).

Mounting Excitement in HCC Examined at ILCA Meeting

September 16th 2017

Theodore H. Welling, MD, shares insight on the top presentations at the ILCA meeting, and how he believes the future will look for the treatment of HCC.

Dr. Montal on Systemic Therapy Advancements in HCC

September 16th 2017

Robert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses advancements regarding systemic therapies in the field of hepatocellular carcinoma (HCC).

Dr. Finn on Current and Emerging Agents in the Field of HCC

September 16th 2017

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, shares insight on some current and emerging agents in the field of hepatocellular carcinoma (HCC).

Finn Highlights Practice-Changing Studies in Liver Cancer

September 16th 2017

The 11th International Liver Cancer Association Annual Conference, taking place September 15 to 17 in Seoul, South Korea, is showcasing multidisciplinary findings across the field of hepatocellular carcinoma.

FDA Approves First Biosimilar for Cancer Treatment

September 14th 2017

The FDA approved the first biosimilar for the treatment of cancer. ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), is indicated for the treatment of colorectal, lung, brain, kidney, and cervical cancers in adult patients.

Emerging Approaches in Liver Cancer

September 8th 2017

Biomarkers in Liver Cancer

September 8th 2017

Immunotherapy in Liver Cancer

September 8th 2017

Ongoing Clinical Trials in Second-Line HCC

September 8th 2017

Second-Line HCC: Unmet Needs

September 8th 2017

HCC: Evolution of Frontline Treatment

September 8th 2017